Radiochemical aspects of alpha emitting radionuclides for medical application-Reference-Cited by-同舟云学术

Radiochemical aspects of alpha emitting radionuclides for medical application

Published:2019-05-22 Issue:9-11 Volume:107 Page:1065-1085
ISSN:2193-3405
Container-title:Radiochimica Acta
language:en
Short-container-title:

Author:

Ferrier Maryline G.¹,Radchenko Valery²³,Wilbur D. Scott¹

Affiliation:

1. Department of Radiation Oncology, Radiochemistry Division , University of Washington , Seattle, WA , USA

2. Life Sciences Division, TRIUMF , Vancouver, BC , Canada

3. Department of Chemistry , University of British Columbia , Vancouver, BC , Canada

Abstract

Abstract The use of α-emitting radionuclides in targeted alpha therapy (TAT) holds great potential for treatment of human diseases, such as cancer, due to the short pathlength and high potency of the α particle, which can localize damage to targeted cells while minimizing effects to healthy surrounding tissues. In this review several potential α-emitting radionuclides having emission properties applicable to TAT are discussed from a radiochemical point of view. Overviews of production, radiochemical separation and chelation aspects relative to developing TAT radiopharmaceuticals are provided for the α-emitting radionuclides (and their generator systems) 211At, 224Ra/212Pb/212Bi, 225Ac/213Bi, 227Th/223Ra, 230U/226Th, 149Tb and 255Fm.

Publisher

Walter de Gruyter GmbH

Subject

Physical and Theoretical Chemistry

Link

https://www.degruyter.com/document/doi/10.1515/ract-2019-0005/pdf

Reference145 articles.

1. Huclier-Markai, S., Alliot, C., Varmenot, N., Cutler, C. S., Barbet, J.: Alpha-emitters for immuno-therapy: a review of recent developments from chemistry to clinics. Curr. Top. Med. Chem. 23, 2642 (2012).

2. McDevitt, M. R., Sgouros, G., Sofou, S.: Targeted and nontargeted α-particle therapies. Annu. Rev. Biomed. Eng. 20, 73 (2018).

3. Lacoeuille, F., Arlicot, N., Faivre-Chauvet, A.: Targeted alpha and beta radiotherapy: an overview of radiopharmaceutical and clinical aspects. Med. Nucl. 42, 32 (2018).

4. Makvandi, M., Dupis, E., Engle, J. W., Nortier, F. M., Fassbender, M. E., Simon, S., Birnbaum, E. R., Atcher, R. W., John, K. D., Rixe, O., Norenberg, J. P.: Alpha-emitters and targeted alpha therapy in oncology: from basic science to clinical investigations. Target. Oncol. 13, 189 (2018).

5. Marcu, L., Bezak, E., Allen, B. J.: Global comparison of targeted alpha vs targeted beta therapy for cancer: in vitro, in vivo and clinical trials. Crit. Rev. Oncol. Hemat. 123, 7 (2018).

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current insights into the implementation of electrochemical sensors for comprehensive detection and analysis of radionuclides;TrAC Trends in Analytical Chemistry;2024-09

2. Scalability study on [133La]LaCl3 production with a focus on potential clinical applications;EJNMMI Radiopharmacy and Chemistry;2024-08-15

3. Development of a²¹³Bi-Labeled Pyridyl Benzofuran for Targeted α-Therapy of Amyloid-β Aggregates;Journal of Nuclear Medicine;2024-07-25

4. Efficient separation of radium from natural thorium using a mesoporous silica-supported composite resin with sulfonic acid groups for the acquisition of targeted α-nuclides 212Pb;Chemical Engineering Journal;2024-04

5. Simultaneous Separation of Protactinium-230 and Uranium-230 Isotopes from a Proton-Irradiated Thorium Matrix;Analytical Chemistry;2024-04-01